Cullinan Oncology (CGEM) 10-Q2022 Q1 Quarterly report

Filed: 16 May 22, 7:11am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: Adimab, agent, Antitrust, ascending, borrow, borrowing, BTD, commensurate, customary, dedicate, degrader, driven, dynamic, embedded, estate, Exkivity, expedient, forecasted, free, functioning, ICFR, immune, implicit, incremental, indemnify, Infection, judgement, lessor, median, Mt, noncancelable, ordinary, peer, promissory, prudent, real, reconciliation, recourse, refinement, refractory, relapsed, ROU, Rybrevant, Sinai, situation, supplemental, tied, toxicology, unlimited, unpaid, unprecedented, unused, vaccine, virulence, waiting

Removed: acquiree, acted, activism, allegation, amivantamab, assertion, attack, attain, automatically, average, barrier, budgeted, calendar, cancelled, capitalization, caution, classify, cMET, collectively, commonplace, comparative, compelling, computational, confirm, connected, consolidate, context, converted, counterclaim, defendant, delaying, deny, deteriorate, deterioration, DFKZ, dividend, downturn, effected, Emergency, epidermal, equally, escalation, ESPP, establishment, Evercore, evidentiary, examiner, exchanged, execution, exercising, exploitation, extract, fall, fluctuated, fluid, Goodwill, governance, guard, HC, hematological, illustrative, importance, incurrence, inform, intentionally, intervention, invalidating, invalidity, invent, IP, irrevocable, leading, learned, led, Leerink, lesser, leveraging, locality, Macau, mandated, meaningfully, misleading, mission, mobocertinib, Morgan, nonrefundable, oncogenicity, oral, outbreak, outlined, outsource, oversee, paper, participating, pattern, perspective, pertaining, pharmacodynamic, pharmacology, physical, postponed, preceding, preemptive, prevalent, purposely, rating, reached, recalculated, receptor, reclassified, recognizable, redeemable, remained, replicated, representation, reserved, resultant, resuming, resumption, retroactively, reveal, safely, safest, settled, showed, spite, split, Stanley, Street, stricter, sum, SVB, tiered, toxicity, trajectory, translation, translational, unemployment, unit, unpatented, unstable, viewed, vivo, Wainwright, Wall, weigh, weighted, wind, withheld, Wuhan

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CGEM similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Cullinan Oncology, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


Date: May 16, 2022	By:	/s/ Nadim Ahmed
		Nadim Ahmed
		President and Chief Executive Officer (Principal Executive Officer)


Date: May 16, 2022	By:	/s/ Jeffrey Trigilio
		Jeffrey Trigilio
		Chief Financial Officer (Principal Financial and Accounting Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.